Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
129.78
+2.00 (1.57%)
At close: Mar 13, 2026, 4:00 PM EDT
128.05
-1.73 (-1.33%)
After-hours: Mar 13, 2026, 5:41 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 22 analysts that cover Neurocrine Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $175.27, which forecasts a 35.05% increase in the stock price over the next year. The lowest target is $140 and the highest is $204.
Price Target: $175.27 (+35.05%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 12 | 12 | 11 | 11 |
| Buy | 8 | 8 | 8 | 6 | 8 | 8 |
| Hold | 1 | 1 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 22 | 21 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $176 → $177 | Buy | Maintains | $176 → $177 | +36.38% | Mar 12, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates $160 | Buy | Initiates | $160 | +23.29% | Feb 24, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $177 → $176 | Buy | Maintains | $177 → $176 | +35.61% | Feb 17, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $169 → $140 | Strong Buy | Maintains | $169 → $140 | +7.87% | Feb 17, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $180 → $175 | Buy | Maintains | $180 → $175 | +34.84% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
3.51B
from 2.86B
Increased by 22.85%
Revenue Next Year
3.87B
from 3.51B
Increased by 9.99%
EPS This Year
6.11
from 4.67
Increased by 30.84%
EPS Next Year
8.29
from 6.11
Increased by 35.71%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.8B | 5.0B | |||
| Avg | 3.5B | 3.9B | |||
| Low | 3.2B | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 33.2% | 42.0% | |||
| Avg | 22.8% | 10.0% | |||
| Low | 13.0% | -4.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 7.57 | 14.81 | |||
| Avg | 6.11 | 8.29 | |||
| Low | 4.26 | 4.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 62.1% | 142.3% | |||
| Avg | 30.8% | 35.7% | |||
| Low | -8.7% | -25.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.